{"slideshow_credits": null, "snippet": "A study of the drug Seroquel XR for patients with borderline personality disorder exposes the tangled mess of interests for academics and universities involved in clinical trials.", "abstract": "Deeply flawed study of anti-psychotic drug Seroquel XR, which initially offered new hope for treating borderline personality disorder, reveals how conflicts of interest among academics and universities can result in messy research; study was financed by AstraZeneca, which manufactures Seroquel, and was overseen by Dr S Charles Schulz, head of psychiatry at Univ of Minnesota with strong ties to pharmaceutical industry.", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Katie", "role": "reported", "lastname": "THOMAS", "rank": 1, "organization": ""}], "original": "By KATIE THOMAS", "contributor": "Jack Begg and Christina Capecchi contributed reporting."}, "web_url": "http://www.nytimes.com/2015/04/19/business/seroquel-xr-drug-trial-frayed-promise.html", "lead_paragraph": "A study of the drug Seroquel XR for patients with borderline personality disorder exposes the tangled mess of interests for academics and universities involved in clinical trials.", "headline": {"main": "A Drug Trial&#8217;s Frayed Promise", "print_headline": "A Drug Trial\u2019s Frayed Promise"}, "_id": "5531430b38f0d86ab80c21ea", "word_count": "2456", "multimedia": [{"height": 126, "url": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbWide-v2.jpg", "legacy": {"wideheight": "126", "wide": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbWide-v2.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 419, "url": "images/2015/04/19/business/19DRUGTRIALJP1/19-DRUGTRIAL-JP1-articleLarge.jpg", "legacy": {"xlarge": "images/2015/04/19/business/19DRUGTRIALJP1/19-DRUGTRIAL-JP1-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "419"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbStandard-v2.jpg", "legacy": {"thumbnail": "images/2015/04/19/business/19DRUGTRIALJP1/19DRUGTRIALJP1-thumbStandard-v2.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2015-04-19T00:00:00Z", "source": "The New York Times", "news_desk": "SundayBusiness", "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "Y", "rank": "1"}, {"name": "subject", "value": "Mental Health and Disorders", "is_major": "Y", "rank": "2"}, {"name": "organizations", "value": "AstraZeneca PLC", "is_major": "Y", "rank": "3"}, {"name": "persons", "value": "Schulz, S Charles", "is_major": "Y", "rank": "4"}, {"name": "subject", "value": "Research", "is_major": "N", "rank": "5"}, {"name": "subject", "value": "Colleges and Universities", "is_major": "Y", "rank": "6"}, {"name": "subject", "value": "Clinical Trials", "is_major": "N", "rank": "7"}, {"name": "organizations", "value": "University of Minnesota", "is_major": "Y", "rank": "8"}], "blog": [], "subsection_name": null, "type_of_material": "News"}